patients

Determining the top ten research priorities in cancer survivorship 2:19
Determining the top ten research priorities in cancer survivorship
Galina Velikova
Benefits of the scientist-patient interaction 2:33
Benefits of the scientist-patient interaction
Martin Christlieb
Interation between patients and researchers: a synergistic exchange 2:04
Interation between patients and researchers: a synergistic exchange
Martin Christlieb
The NCRI Living with and Beyond Cancer Initiative 1:16
The NCRI Living with and Beyond Cancer Initiative
Galina Velikova
Improving approaches for cancer survivorship 1:03
Improving approaches for cancer survivorship
Galina Velikova
NCRI educational session initiatives 1:23
NCRI educational session initiatives
Elaine Vickers
Making the patient voice heard 1:14
Making the patient voice heard
Elaine Vickers
Promoting patient involvement through education 1:11
Promoting patient involvement through education
Elaine Vickers
Uncovering the genomic landscape of prostate cancer 1:39
Uncovering the genomic landscape of prostate cancer
Joaquin Mateo
Interesting topics presented at ESMO 2017 3:24
Interesting topics presented at ESMO 2017
Fatima Cardoso
Drug shortages around the world: why communication is key 1:22
Drug shortages around the world: why communication is key
Fatima Cardoso
Why should physicians and patients be educated about novel drugs? 0:43
Why should physicians and patients be educated about novel drugs?
Eric Jonasch • 8 Sep 2017
What have we learned from recent clinical trials in early breast cancer treatment? 4:13
What have we learned from recent clinical trials in early breast cancer treatment?
Elzbieta Senkus-Konefka
Genomic aberrations in prostate cancer 0:50
Genomic aberrations in prostate cancer
Joaquin Mateo
PARP inhibitors: their applications and efficacy against prostate cancer 1:25
PARP inhibitors: their applications and efficacy against prostate cancer
Joaquin Mateo
When is the optimal time to use PARP inhibitors in prostate cancer patients? 0:57
When is the optimal time to use PARP inhibitors in prostate cancer patients?
Joaquin Mateo
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals